NCT02367859View on ClinicalTrials.gov

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

November 5, 2018

Study Completion Date

June 26, 2019

Conditions

AmeloblastomaBRAF Gene Mutation

Interventions

DRUG

Dabrafenib

Given PO

DRUG

Trametinib

Given PO

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Stanford University

OTHER